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CHAPTER I 
THE RESEARCH PROBLEM 
Introduction 
Perinatal deaths in cattle associated with dystocia are of great 
economic importance to the cattle industry. Dystocias were responsible 
for 70 percent of all deaths at or near birth in Australia, and this 
amounted to 45 percent of all losses including abortion, stillbirth, and 
postnatal death (1). Similar figures of 60 percent and 38 percent have 
been reported by Patterson and Bellows (2). In all reports, most of the 
dystocia cases were first calf heifers. Reducing this mortality would 
be of substantial economic importance to the United States cattle indus-
try. 
Clenbuterol (Planipart™, NAB 365) is a highly specific, unusually 
long-acting (four to eight hours) , sympathomimetic B2 receptor stimu-
lator. Its effects result in bronchodilation and tocolysis, i.e., the 
temporary paralysis of myometrial contractility. The tocolytic effect 
has been explored in the bovine and ovine for the short-term postpone-
ment of parturition to socially more acceptable hours and as an aid in 
resolving complicated parturitions or in obstetrical surgery. During 
large-scale field trials for postponement of parturition, the observa-
tion has been made by investigators that subsequent deliveries were easy 
and uncomplicated. Hence, an objective evaluation of the effect of 
Clenbuterol on the characteristics of deliveries in heifers bred to a 
l 
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bull with a known high index for dystocia would be warranted. Evalua-
tions should include: (1) potential effects of the drug on the bony and 
soft tissue components of the birth canal, (2) the duration of stages I, 
II, and III of parturition, (3) the frequency of dystocia, (4) still-
birth rate, (5) calf viability, and (6) the restoration of postpartum 
fertility. 
Assumptions--Null Hypotheses to be 
Tested for the Evaluation 
of NAB 365 
#1. No effect of the drug on dystocia rate. 
#2. No effect of the drug on pelvic area. 
#3. No effect of the drug on Stage I of parturition. 
#4. No effect of the drug on Stage II of parturition. 
#5. No effect of the drug on Stage III of parturition. 
#6. No effect of the drug on calf viability. 
Observations will be made on the cattle by the major investigator 
with the help of senior veterinary student technicians. This will place 
an unavoidable human error in the results based on different individu-
als' ability to detect cows in the first stage of parturition. Another 
limitation will be if the expected dystocia from the A.I. sire does not 
occur. 
Definition of Terms 
Tocolysis: The temporary paralysis of myometrial contractions. 
Pelvimeter: A device used to take horizontal and vertical pelvic 
measurements per rectum or vagina. 
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Stages of Parturition: (I) Active contractions of both longitudi-
nal and circular muscle fibers of the uterine wall and the dilation of 
the cervix. (II) Entrance of the fetus into the dilated birth canal, 
rupture of the fetal membranes, and expulsion of the fetus through the 
vulva. (III) Expulsion of the fetal membranes and involution of the 
uterus. 
CHAPTER II 
REVIEW OF THE LITERATURE 
Introduction 
The hormonal control of parturition appears to be a cascade of 
events, each step building on the next step, bringing about termination 
of pregnancy and expulsion of the fetus. The signal that initiates the 
cascade begins in the fetus and creates a response from the maternal 
endocrine system. In the bovine, much of the detail in the cascade of 
events lacks documented proof but, using what is known about similar 
species such as the goat and sheep, one can postulate the events leading 
to parturition. 
Hormonal Control of Parturition in the Bovine 
Role of the Fetus--Pituitary Adrenal Axis 
The role of the fetus in timing the initiation of parturition is 
well accepted in most (cow, sheep, pig, and goat) domestic species 
(3, 4, 5, 6, 7, 8, 9, 10, 11). 
The importance of an intact pituitary-adrenal axis in the fetus for 
initiation of parturition has been well established for cows (12, 13). 
Premature parturition will occur when nhe fetal adrenal is stimulated 
with corticotrophin (14, 15) and with continuous administration of 
dexamethasone into the fetus (14, 16). When parturition was induced by 
4 
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the administration of dexamethasone to the fetal calf, the rise in 
estrogen and fall in progesterone in maternal circulation was similar to 
that seen at normal parturition (14, 16). These observations suggest 
that activation of the fetal pituitary-adrenal axis is responsible for 
the initiation of parturition in the cow (8). 
The control of the fetal pituitary-adrenal axis has best been 
described in the sheep. In the intact fetus, cortisol production at 
term appears to be a result of changes in maturation of the fetal adre-
nal plus an increasing release of ACTH from the fetal pituitary (5, 17). 
The increasing release of ACTH acts on the fetal adrenal stimulating 
increasingly higher levels of cortisol production as the adrenal gland 
matures (4, 5). There is a gradual rise in the concentration of corti-
sol in the fetal plasma beginning 10 to 15 days prepartum, which cul-
minates in a more rapid rise during the last two to three days of gesta-
tion (18). Similar changes in fetal cortisol levels are documented in 
the bovine (14, 16). 
The rise in fetal cortisol acts as the signal to the dam that the 
fetus is ready for expulsion. Rising fetal cortisol levels also act to 
prepare the fetus for survival outside the uterine environment. Inves-
tigators have demonstrated the fact that glucocorticoids accelerate lung 
maturity by the appearance of pulmonary surfactant (19). Glucocorti-
coids are also known to be involved in the maturation and biochemical 
differentiation of other tissues in the fetus (4) . 
In initiating the events that lead to parturition, fetal cortisol 
appears to act on the placenta. The mechanism of action on the placenta 
by fetal cortisol in the domestic species is still under debate in the 
literature. In sheep, the action of rising fetal cortisol on the 
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placenta is well understood. Species (goat, cow, pig) which depend on 
the corpus luteum as the major source of progesterone have not received 
as much attention, and much of the action of fetal cortisol is theo-
retical. By using the sheep as a model and pointing out the differences 
in the corpus luteum dependent species, a potential picture of the 
action of rising fetal cortisol levels on the bovine placenta can be 
drawn. 
In sheep, the major source of progesterone is the placenta after 
day 50. The increase in fetal cortisol production during the last seven 
to ten days of pregnancy is closely followed by a decrease in maternal 
progesterone during the last one to four days and by an increase in 
unconjugated estrogen during the last 24 hours of gestation. Evidence 
is accumulating that the rising fetal cortisol may be responsible for 
both the fall in progesterone and rise in estrogens through a direct 
affect on placental steroidogenesis and that this is the mechanism which 
influences the onset of labor (4, 20, 21). 
The ovine placenta does become a complete endocrine gland capable 
of producing increasing amounts of estrogen in the absence of an in-
crease in either maternal or fetal adrenal C-19 precursors (5). The 
placenta late in gestation secretes C-21 steroids (progesterone) and 
little unconjugated estrogen. In response to rising fetal cortisol 
concentrations, the placenta becomes capable of synthesizing estrogens 
from C-21 (progesterone) precursors by activating 17-alpha hydroxylase, 
C-17,20 lyase, and aromatase enzyme systems in the placenta. The enzyme 
system activity increases as fetal cortisol increases. The enzyme 
changes have been shown to occur In Vivo and In Vitro following spon-
taneous increases in endogenous fetal cortisol and/or following exogen-
ous fetal infusion of cortisol (4, 5, 6, 7, 10, 20, 21, 22). Although 
actual demonstration of estrogen production In Vivo has not occurred, 
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the increased activity of the enzymes necessary for the conversion of 
progesterone to. estrogen and demonstration In Vivo of metabolites from 
C-21 steroid (progesterone) reduction to C-19 steroids (estrogen) leads 
investigators to conclude that the pathway exists and is being utilized 
in the ovine (5). Other evidence which points to progesterone metabolism 
as a possible route for estrogen synthesis is that progesterone produc-
tion remains constant while metabolism increases in late gestation (7). 
The statement that fetal cortisol alters ovine placental steroido-
genesis to initiate parturition may be an oversimplification. Kendall 
et al. (23) found that when hypophysectomized fetuses received ACTH, the 
normal fall in progesterone and rise in estrogen failed to occur thus 
implicating the hypothalmic and possibly pituitary factors in conjunc-
tion with fetal cortisol. 
In the goat, cow, and sow, the predominant source of the proges-
terone necessary for the maintenance of pregnancy is produced by the 
corpus luteum. In these species, a rise in maternal estrogen and fall 
in maternal progesterones precedes parturition. A rise in fetal corti-
sol appears to trigger these maternal endocrine changes as in the sheep 
(14, 24). 
Most of the work in the corpus luteum dependent species has been 
done in the goat. It has been proposed that the rising fetal cortisol 
levels activate enzymes in the placenta as in the sheep, leading to 
increased placental estrogen secretion. Flint et al. (25) showed that 
the increase in fetal cortisol levels preceding parturition activates 
the 17-alpha hydroxylase enzyme system in the caprine placenta and thus 
the increasing estrogen production. 
The goat's placenta is unlike the sheep in that it rapidly meta-
bolizes progesterone to 5-beta pregnanediols In Vitro. However, like 
the sheep, exposure to either exogenous or endogenous glucocorticoids 
usually results in the formation of more polar 17-alpha hydroxylated 
progesterone metabolites indicating a metabolism and/or conversion 
similar to the fetal cortisol response in the ovine. These extracts 
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are not formed when parturition is induced with prostaglandin which 
by-passes fetal cortisol increases (25). There appears to be a rela-
tively minor activation of C-17-20 lyase enzymes in the goat as com-
pared to the ovine (6). After exposure to glucocorticoids, the caprine 
placenta contains the enzymes necessary for synthesis of estrogens which 
are rising dramatically as fetal cortisol increases (3, 25). However, 
there is no In Vivo evidence for placental production of estrogens be-
cause no difference between arterial and venous levels has been detected 
(6, 10). 
Another possible action of rising fetal cortisol is the effect it 
has on caprine placental lactogen. Buttle et al. (26) has identified 
this lactogen of placental origin in the caprine, and it has been shown 
to be associated with luteal support late in gestation (27) . Early 
evidence indicates that increased fetal adrenal activity causes a de-
crease in caprine placental lactogen production (3). 
In the bovine, fetal cortisol increases dramatically during the 
last ten days of gestation (14, 16). The bovine is similar to the 
caprine in placentation, enzyme systems, and endocrine control of par-
turition. Also, the placenta metabolizes progesterone in large quan-
tities and is thought to respond to fetal cortisol similar to the goat 
( 6) • 
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Maternal Role in Parturition 
The maternal role in parturition can be described as completing 
a process initiated by a signal from the fetus. The process carried 
out by the darn is seen as a fall in progesterone, a rise in estrogens, 
peaking prostaglandin levels just prior to parturition, and increases in 
oxytocin release just prior to and during parturition (11). Again, most 
of the work has been done in the caprine as an example for the bovine 
because of the similarities in the two species. 
Luteal Support 
Maintenance of the corpus luteum appears to fall into two cate-
gories in the caprine: Placental origin and pituitary origin. 
Placental Origin. From the placenta, there appears to be a sub-
stance, caprine placenta lactogen (CPL) which is necessary for luteal 
support during pregnancy (26). Withdrawal of the source via hyster-
ectomy during the last third of pregnancy causes abrupt declines in the 
circulating levels of progesterone. Progesterone levels fall to less 
than 50 percent of the normal prevailing levels in the intact pregnant 
goat (24) . This suggested that hysterectomy removed luteal trophic 
support normally present during pregnancy. Buttle et al. (26) obtained 
evidence to identify and support the existence of CPL. Cowie et al. 
(29) demonstrated that the placental lactogen must work in conjunction 
with maternal pituitary factors (LH) since hypophysectomy results in 
abortions. A more recent study of placental lactogen in goats using 
radioreceptor assays has indicated that CPL was present in high concen-
trations throughout the latter two-thirds of pregnancy (30) . The 
correlation between CPL plasma changes and progesterone changes is not 
close, but this does not exclude a luteotrophic role for the hormone. 
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It has been noted that CPL concentrations fell progressively during the 
last 15 days of pregnancy when corticosteroid concentrations were rising 
in fetal circulation. Similar changes, but more abrupt, were noted when 
corticotrophin was administered to the fetal goat raising the possi-
bility that increasing fetal cortisol levels might inhibit the ability 
of the placenta to elaborate CPL (30, 31). If CPL is the placental 
luteotrophin in the goat, its withdrawal may act in conjunction with 
discrete prostaglandin F2a (alpha) (PGF) releases to initiate luteo-
lysis (31). 
In the bovine, the structure of bovine placental lactogen has been 
reported (32). Initial work, however, has not indicated it to be luteo-
trophic (33) . 
Pituitary Origin. The maternal pituitary gland is also essential 
for luteal support in the pregnant goat. Hypophysectomy results in 
abortion while hypophysectomy followed by LH replacement resulted in 
the pregnancy being maintained (27). 
Progesterone 
The source of progesterone in both the caprine and bovine is the 
corpus luteum (8, 10). Prior to parturition, the concentration of 
progestagins in maternal blood plasma decreases gradually during the 
last 20 days of gestation and falls dramatically two to three days 
before parturition (34). The regression of the corpus luteurn and drama-
tic fall of progesterone two to three days prior to parturition is the 
subject drawing the most interest in the literature. 
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Late in gestation, uterine arterial progesterone levels are greater 
than uterine venous progesterone levels. Thorburn (3) suggested that 
the placenta is using the progesterone as a precursor for estrogen 
synthesis. By measuring the arterial-venous progesterone difference, 
evidence has been presented that the gravid caprine uterus extracts 
significant quantities of progesterone from maternal circulation (35, 36). 
Thorburn and Schneider (36) showed that the arterio-venous difference in 
progesterone decreased as gestation increased and, in one case, the 
venous concentration of progesterone was actually greater than the 
arterial concentration. Although the number of animals was small, they 
suggested that in late gestation the caprine placenta produced small but 
increasing amounts of progesterone which would decrease the arterial-
venous difference in progesterone concentration. Another possibility 
is that the placental uptake of progesterone is decreasing. Ainsworth 
and Ryan (37) and Wiener (38) have shown that In Vitro the bovine pla-
cental tissue is capable of synthesizing progesterone. 
The dramatic fall in progesterone coincides with the regression of 
the corpus luteum which will be discussed later. 
Another action of progesterone appears to be inhibition of prosta-
glandin release. In cycling ewes, repeated administration of exogenous 
progesterone resulted in an increase in prostaglandin release with each 
fall in progesterone. In cycling ewes, repeated administration of 
exogenous progesterone resulted in an increase in prostaglandin release 
with each fall in progesterone. The mechanism for the suppression of 
prostaglandin release by progesterone is unknown (31). 
The effect of progesterone on the myometriurn to prevent myometrial 
contractions appears to be mediated through controlling calcium ion 
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transport across the cell membrane. At the present, calcium ions are 
the only known stimulant which directly triggers the actinomyosin-ATP 
interaction and thus initiates the cyclic myometrial contractile force 
of labor. Progesterone promotes binding of this "activator calcium" 
and raises the threshhold of excitement. Prevention of the activator 
calcium from initiating myometrial contractions occurs even in the 
presence of high levels of exogenous prostaglandin which normally lowers 
the threshhold of excitement and allows inflow of calcium ions into the 
cell (39). 
Estrogens 
The role of estrogens in the initiation of parturition is receiving 
more interest in the literature. The unconjugated estrogens first 
appear in significant amounts in maternal plasma around days 40 to 50 of 
gestation in the goat. Estrogens continue to increase steadily during 
pregnancy before undergoing a rapid increase over the last four to five 
days prior to parturition (31, 40, 41, 42, 43). The estrogens present 
in the fetal and maternal goats are mainly estrone and estradiol 17-
alpha, both considered biologically weak, and variable amounts of estra-
diol 17-beta (41). Flint et al. (25) has shown that estradiol 17-beta 
follows .a similar pattern of increase as the estrone and estradiol 17-
alpha prior to the dramatic fall in progesterone in normal parturition. 
The source of rising estrogen concentration late in gestation is 
the placenta (3) . Under the influence of fetal cortisol, the caprine 
placenta possesses the enzymes necessary for the production of estrogen. 
Although no actual increase of In Vivo estrogen production has been 
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documented, the probability cannot be dismissed that the placenta is 
in fact producing estrogen, possibly from progesterone precursors (3, 
10). Recently, a large increase in mammary estradiol 17-beta has been 
demonstrated near term (44) . Whether this represents De-novo synthe-
sis or formation from placental precursors is not known (10) . 
The action of estrogens in the control of parturition are varied. 
The possibility arises that estrogens play a dual role in control of 
the corpus luteum. The CL of the pregnant rat is supported in part by 
a placental lactotropin, which may act by increasing estrogen receptors 
on the CL, and the increase in estrogen availability raises the LH 
receptor population. A similar situation may exist in the goat, in 
which the progressive increase in estrogen concentrations may lead to a 
luteotrophic complex late in gestation, since the estrogens are pri-
marily fetal or fetoplacental in origin (5) . Studies have also shown 
that estradiol 17-beta is luteolytic in the goat (31). The luteolytic 
role of estradiol 17-beta operated through prostaglandin production and 
release causing luteal regression. Physiological amounts of estradiol 
17-beta injected into pregnant goats increased prostaglandin levels in 
the utero-ovarian vein and resulted in indirect luteal regression (45). 
The paradoxical actions of estrogens (luteolytic or luteotrophic) in the 
pregnant goat may well be related to the presence or absence of certain 
estrogen receptors in the CL. The estradiol receptor population may be 
regulated by caprine placental lactogen which decreases late in gesta-
tion in response to fetal cortisol (3). 
The action of estradiol 17-beta causing the release of prostaglan-
din may come from the estradiol 17-beta traversing the placental barrier 
and acting on estrogen receptors in the maternal placenta which responds 
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by increased production of PGF. This estrogen receptor population in 
the placenta and endometrium may be regulated by progesterone levels 
(3). In the event of falling progesterone levels, the estrogen recep-
tor population in the placenta would be increasing, amplified by itself, 
since estrogen is known to induce its own receptors (25). 
Similar changes in estrogen levels in the cow lead to the assump-
tions that the action of estrogens are much the same as the goat. The 
major site of estrogen production is likely the placenta (14, 46). In 
the cow, it appears that estradiol 17-beta plays an important role in 
the initiation of parturition and particularly in the delivery of the 
placenta and membranes (8) • The estrogens causing lysosomal breakdown 
releasing hydrolase enzymes causing dissolution of the maternal placen-
ta and separation of the membranes (31). 
Estradiol may also play an important role in oxytocin receptor 
population control in the placenta and myometrium (45). Roberts et al. 
(47) have shown that in sheep the oxytocin receptor population in the 
endometrium and myometrium varies during the estrous cycle and that 
estrogen increases their concentration. 
Prostaglandins 
The role of prostaglandins in pregnancy and parturition appears to 
be dual: (1) lysis of the corpus luteum, and (2) causing contracture 
of the myometrium (5). 
The source of the prostaglandins appears to be the fetal membranes 
and maternal endometrium. In the pregnant uterus, 83 percent of the 
blood flow goes to the cotyledons, 3 to 4 percent to the myometrium, 
and 13 to 14 percent to the endometrium, suggesting that the myometrium 
is not a significant source to the PGF levels. Also, In Vitro PGF 
production by the myometrium is only 25 percent of that produced by 
the maternal cotyledons (48, 49). 
The role of the fetal membranes in the production of prostaglan-
dins is not clear. Prostaglandin concentration in amnionic fluid in-
crease during parturition and may reflect prostaglandin production of 
the amnion. Prostaglandins placed in the amnionic cavity can induce 
abortions (50, 51). Thus, speculations are drawn that prostaglandins 
produced in the intercotyledonary endometrium and fetal membranes may 
have a direct stimulating effect on the myometrium by diffusion. It 
is not clear if the diffusion may also be from the endometrium to the 
amnionic fluid (5). 
The dual role of prostaglandins begins with lysis of the corpus 
luteum. This role is still debated in the literature. Hoffman (11) 
states that the prostaglandin release appears to be a coincidence of 
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the prepartum progesterone decline rather than a cause. Other investi-
gators believe and present evidence that the prostaglandins are indeed 
the primary luteolytic factor in the corpus luteum dependent species. 
The controversy develops around the timing of the prostaglandin re-
lease. Investigators have documented intermittent peaks of PGF release 
superimposed on the general increase in PGF, similar to levels observed 
in non-pregnant cycling ewes at the time of luteal regression (41, 54). 
Initial release of the prostaglandin occurred before any significant 
decrease in plasma progesterone levels. Further rises in PGF levels 
follow as progesterone levels decrease. Umo et al. (54) have suggested 
that the initial PGF increases occur 48 hours prior to term delivery and 
precedes the decrease in progesterone levels by 18 to 22 hours. Currie 
and Thorburn (31) examined and found that the small amounts of PGF 
found in the uterine vein were luteolytic causing luteal regression 
and abortion. 
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Prostaglandin synthesis and release appears to be under the control 
of changes in placental progesterone and estrogen production (5). As 
has been previously stated, progesterone blocks prostaglandin release, 
and estradiol 17-beta stimulates production and release. In experiments 
by Liggins et al. (52), the estrogen-induced release of prostaglandin 
was blocked by pharmacological amounts of progesterone (200 mg./day). 
However, the rise in the concentration of prostaglandins in the myo-
metrium and maternal cotyledon was not suppressed indicating that pro-
gesterone appeared to inhibit release but not the synthesis (52). 
Investigators have speculated that the route by which the prosta-
glandins reach the myometrium is by systemic blood flow. Liggins (52) 
failed to demonstrate a counter-current system. During labor, when 
large amounts of prostaglandins are being released, significant amounts 
(two to three ng./ml.) were present in the jugular vein, escaping meta-
bolism in the lung and systemic dilution (31). Although the systemic 
route may appear wasteful, alterations in the sensitivity of the target 
organs would allow low levels of prostaglandins to be effective. During 
the last 24 hours of gestation, the sensitivity of the myometrium in-
creases markedly due to a decrease in plasma progesterone and an in-
crease in estrogen levels. Thus, the low arterial levels of prosta-
glandin may be sufficient to exert a direct stimulation effect on the 
myometrium since the progesterone block is removed and the myometrium 
is estrogen primed (53). 
The role of prostaglandin in myometrial contractions involves 
calcium ion transport. PGF lowers the excitation threshhold allowing 
calcium ions to activate actinomyosin and ATP for contractions. The 
presence of progesterone blocks this effect, even in the presence of 
PGF by raising the threshhold for calcium transport (39). 
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Another role prostaglandin appears to play is relaxation of the 
cervix. In the presence of low progesterone levels, infusion of prosta-
glandins into the arterial blood supply of the uterus and cervix of 
sheep resulted in cervical relaxation (55). 
Oxytocin 
The source of oxytocin is the posterior pituitary. Oxytocin plays 
an important role in the second stage of labor. Distension of the 
vagina and cervix is known to cause release of oxytocin (56, 57). An 
attempt was made.by Flint et al. (59) to show a relationship between 
PGF and oxytocin release. It was shown that after vaginal distension 
the oxytocin release preceded the PGF release by one minute. It has 
also been shown that infusions ot oxytocin cause increases in PGF in 
the utero-ovarian vein (60) • 
The release of oxytocin in response to vaginal distension is en-
hanced by estrogen and inhibited by progesterone (61). The massive 
releases of PGF during labor allows some of the PGF to escape metabolism 
and stimulate oxytocin release in a positive feedback cascade (31, 62). 
Oxytocin functions by causing an influx of the activator calcium 
into the cell. This activator calcium stimulates energy release from 
ATP for the contraction of the actinomyocin filaments (58). 
The primary function of oxytocin would be to induce myometrial 
contractions. Contractions of the myometrium force the fetal membrane 
against the softened cervix and result in cervical dilation. 
Neuronal Control of Parturition 
Neuronal control of the genital tract is by the autonomic nervous 
system. Also, there are sensitive nerve fibers in the uterine cervix 
and dorsal vagina that stimulate the release of oxytocin and abdominal 
muscular pressure during labor (63) . 
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Autonomic nerve fibers originate in the last thoracic and first 
lumbar spinal cord segments and travel to the genital tract via the 
hypogastric nerve. Preganglionic sympathetic fibers synapse in the wall 
of the genital tract. Postganglionic fibers then travel to effector 
sites. Sympathetic nerves supply the myometrium of the genital tract, 
but parasympathetic nerves supply only the cervix and vagina, not the 
myometrium (63) and would have no effect on uterine motility. 
The smooth muscle of the uterus contains two types of receptors: 
alpha and beta. The alpha receptors are primarily excitatory, and the 
beta receptors are primarily inhibitory (63). Alpha receptors have a 
specific affinity for norepinephrine and stimulate organ function while 
beta receptors have a specific affinity for epinephrine causing inhibi-
tion of organ function (58, 63). Beta receptors are found in larger 
numbers in uterine and respiratory tract smooth musculature (58) . Stor-
age granules of norepinephrine which are normally found at the post-
ganglionic nerve endings are depleted during the last two-thirds of 
pregnancy, thus preventing local release of norepinephrine and contrac-
tion of the myometrium. However, systemic catecholamine release from 
the adrenal medulla (predominantly epinephrine) may cause the stimulation 
of the beta receptors and inhibit myometrial contractions during parturi-
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tion via a systemic route rather than a neural route (63) • Catechola-
mine release during the last third of pregnancy is primarily epinephrine, 
since the amount of epinephrine synthesized in the adrenal medulla is 
controlled by corticosteroid levels which increase the conversion of 
norepinephrine to epinephrine. 
According to studies by Land et al. (64), there are two distinct 
types of beta receptors, called beta-1 and beta-2. Beta-1 receptor 
stimulation results in cardiac stimulation, an increase in lipolysis, 
and the relaxation of intestinal smooth muscle. The beta-2 receptor 
stimulation causes brochodilatation, relaxation of the uterus, vasodi-
latation, and glycolysis. These receptors have not been identified 
histologically but are characterized by distinct pharmacological 
responses. 
Literature Review--Beta-2 Mimetic 
Clenbuterol (Planipart™) 
NAB 365 
Planipart™ (4-amino-alpha tert-butyl amino methyl 35-dichlorben-
zylalcohol-hydrochloride) is highly specific for beta-2 receptors and 
acts for long durations (58) . Since its action is selective for beta-2 
receptors, it has been found to be useful for the control and treatment 
of bronchial asthma in man and as a reliable bronchodilator in horses 
(58, 65). Its effects in other species include: (1) bronchodilatation 
in guinea pigs, cats, and dogs, (2) beta mimetic effects on the gut of 
guinea pigs, mice, and rats, (3) dose-related decreases in blood pressure 
in cats and dogs of shorter duration than the broncholytic dilation 
effect, and (4) In Vitro tocolysis at low doses of the rat uterus. In 
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Vivo tocolytic and broncholytic effects are identical (58). In compari-
son with other beta mimetic agents, lowering of blood pressure and the 
compensatory increases in heart rate are much less pronounced and of 
short duration with Planipart™ (66). 
Studies have shown that Planipart™ acts fast and comparatively 
long. Zerobin and Kundig (59) have treated cattle, pigs, and sheep 
. h 1 . TM wit P anipart They were attempting to delay parturition in cattle 
by treating at differing intervals in parturition up to and into the 
beginning of Stage II of parturition. Immediately after treatment, all 
animals calmed down with a reduced respiratory rate and spontaneous 
lying down. They reported an average delay time by measuring taco-
graphic contractions of the uterus of 195 minutes; then labor was re-
sumed with the disappearance of the drug, and deliveries did not differ 
from spontaneous parturition. Their subjective evaluation of Stage II 
was that Stage II appeared to be easier, faster, and less painful in 
heifers. They reported that widening of the birth canal and cervix 
continued during tocolysis. Offspring viability was not affected. 
Parturition in sows was interrupted after one to three piglets had 
already been delivered. After the resumption of labor, the piglets were 
delivered quickly with the interval between piglets being shorter versus 
those recorded before treatment. No undue side effects were noted on 
piglet viability, placenta delivery, lactation, and maternal behavior. 
Zerobin and Kundig (58) reported clinical observations in two ewes 
with dystocias and confirmed that Planipart™ completely suppressed 
the myometrial contractility for up to three hours. 
. f . TM b Studies have shown that the tocolytic ef ect of Planipart may e 
reversed by oxytocin, but only after the tocolytic effect has begun to 
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weaken. The pharmacodynamic effect of oxytocin is mediated via specific 
receptors and is dependent on membrane potentials as well as the intra-
cellular content of calcium. Beta mimetic compounds stimulate the ade-
nylcyclase system in the cell membranes which results in an outflow of 
calcium from myometrial cells, causing relaxation. Oxytocin competes 
with the beta mimetic compounds for the control of calcium. 
In non-controlled clinical studies, Ballanine et al. (67) reported 
h ff f 1 ' TM . l' . 1 . . on t e e ect o P anipart in c inica situations: (1) uterine pro-
lapse (eight cases), (2) uterine hemorrhage (five cases), (3) torsion of 
the uterus (four cases), (4) dystocia due to fetal malposition (four 
cases), (5) dystocia due to fetal oversize (twelve cases) , (6) dystocia 
due to spasm of uterine cervix (seven cases) , (7) retained placenta (seven 
cases) , and (8) preparation of caesarian section (nine cases) • The re-
corded observations are as follows: (1) Uterine prolapse (eight cases). 
At the dose of 0.5 mg. parentally of NAB 365, within 30 minutes a com-
plete reduction of uterine contractions and uterine replacement was 
easier. (2) Postpartum hemorrhage (five cases). Parental administra-
tion of 0.5 mg. of NAB 365 in conjunction with anticoagulation therapy 
reduced uterine contractions and helped stop clot expulsion. Uterine 
contractions which increase blood return were stopped, and clot separa-
tion and expulsion were reduced. (3) Dystocia due to uterine torsion 
(four cases) • Reduction of the uterine contractions aided manual reduc-
tion of the torsion. (4) Dystocia due to malposition (four cases) . 
Reduction of uterine contractions aided obstetrical manipulations, and 
manual delivery completed parturition. (5) Dystocia due to fetal over-
size (twelve cases). In five cases, ease of fetal manipulation was 
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gained for manual delivery. Seven cases had caesarians, and abolition 
of contractions facilitated intervention. (6) Dystocia due to spasm 
of the uterine cervix (seven cases) . Treatment before membrane rupture 
suppressed uterine contracture for seven to eight hours. When parturi-
tion resumed, it concluded normally in six cases. (7) Retained placenta 
(seven cases). Low doses were used (0.2 to 0.3 mg.) to avoid inertia 
when attempting to manually separate the placenta and ease powerful con-
tractions. (8) Preparation for caesarian section. Ease of operation 
has been noted. 
Verhulsdonk (68) used Planipart™ in a clinical trial to reduce 
night calving. Heifers were treated daily from the 278th day and cows 
daily from the 280th day (or sooner if the course of pregnancy dictated) . 
186 animals were used in a controlled experiment and received a placebo 
in the same manner. By using the beta-2 mimetic drug systemically at 
9 P.M., night calving was reduced 46.8% (p < .001) in comparison to the 
controlled group. Comparisons between the two groups showed that NAB 
365 worked effectively for a period of 14 hours. Another subjective ob-
servation was easier calving in first calf heifers because of better 
stretching of the birth canal. No effect on calf viability, Stage III 
of parturition or clinical appearance of the cows was noted. 
Greene (69) used clenbuterol in a clinical trial to postpone par-
turition. In cows with a cervical diameter at treatment of less than or 
equal to the width of a hand. Clenbuterol delayed parturition at least 
5.2 hours compared to control animals. In cows with a cervical diameter 
that permitted part of the fetus through the reported delay was only two 
hours. Clinically there was no difference in dystocia rates between 
treatment and control groups. Greene also used clenbuterol to reduce 
night calving. 127 cows were treated at midnight if they were not 




MATERIALS AND METHODS 
Population 
Seventy-one Hereford cows were chosen for the study. Of the 71, 
51 cattle were included in the trial. Two cows aborted; eight cows 
calved before treatment could be initiated; three cows calved too late 
to be included in the study; and seven cows that were initially measured 
for use in this study were not used. Five heifers were removed for 
statistical analysis. Of the 51 cattle used in the trial, 43 were 
first-calf heifers, and eight were second-calf heifers. 
A minimum of 30 heifers thought to be settled to a Hereford bull 
that sired heavy birth weight calves were assigned to the study during 
May 1980. The remaining heifers were bred to an Angus bull of unknown 
progeny birth weights. 
All heifers were assigned to the same pasture and nutritional 
regimen. They were expected to gain the approximate weight of calf and 
uterine fluids during the last three or four months of gestation and 
were expected to be in good body condition at calving. 
Type of Control 
The type of control was double-blind, randomized. 
The 71 experimental animals were assigned to two groups in a-car-
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dance with their pelvic size (above A or below B average). Animals 
calved in sequence due to insemination dates (sire one first and sire 
two thereafter). 
Heifers in groups A and B exhibiting pending parturition were 
assigned in numerical sequence to the treatment specified on the 





Animal No. Code for Animal No. 
Code for 
Treatment Treatment 
1 I 19 I 
2 T 20 D 
3 0 21 T 
4 D 22 L 
5 p 23 T 
6 w 24 F 
7 A 25 p 
8 H 26 0 
9 c 27 H 
10 F 28 I 
11 L 29 w 
12 K 30 c 
13 w 31 F 
14 H 32 D 
15 c 33 L 
16 0 34 K 
17 K 35 A 











l A 19 T 
2 D 20 w 
3 K 21 L 
4 w 22 0 
5 H 23 K 
6 0 24 I 
7 I 25 c 
8 A 26 p 
9 c 27 H 
10 p 28 L 
11 T 29 T 
12 0 30 F 
13 F 31 I 
14 L 32 D 
15 w 33 p 
16 R 34 H 
17 D 35 K 
18 A 36 c 
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A placebo was utilized for control to eliminate anticipation of 
1 1 . TM d 1 b 1 . l' d d d resu ts. P anipart an p ace o so utions were supp ie preco e 
with the letters A, C, D, F, H, I, K, L, O, P, T, and W by Boehringer 
Ingelheim Ltd. As the study progressed, technicians recognized treated 
heifers on the basis of delayed parturition but, since a blind study 
is being conducted, they cannot anticipate results of treatment. 
Dose, Route, and Duration 
Single intramuscular injection of either Planipart™ 0.8 mcg./kg. 
(0.0267 ml./kg. of solution containing 30 mcg./ml.) or placebo 0.0267 
ml./kg. were used. 
Method of Evaluation 
Pelvic Areas 
Pelvic areas were taken at approximately seven months of gestation. 
This was done per rectum taking vertical and horizontal diameters and 
multiplying these for a relative pelvic area (70). Heifers were strati-
fied into the top 50 percent and lower 50 percent areas for assignment 
to treatment groups. Pelves were also measured at prepartum treatment 
and immediately postpartum. 
Observation of Parturition and Treatment 
Heifers were observed during the last ten days of gestation three 
times daily for pending parturition. When parturition was imminent 
(distended udder, relaxed sacrosiatic ligaments, release of cervical 
plug), they were observed every two hours for signs of the first stages 
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of labor. This was confirmed by vaginal examination. If the cervix was 
dilated five centimeters or more, the heifer was treated with placebo or 
1 . TM . 1 1 P anipart intramuscu ar y. Stage of labor, including cervical dila-
tion at treatment, and the times of the above episodes were recorded. 
The heifers were placed in a pen to continue parturition. The 
second stage of labor (abdominal press and presentation of fetal mem-
branes--water sac at the vulva) was the next benchmark event. To stan-
dardize the observations for the beginning of the second stage of par-
turition, the landmark used to give consistency among the observers was 
the presence of fetal membrane visible in the vulva. However, observa-
tions were recorded a minimum of every two hours from treatment to 
parturition. 
Once the water sac was observed at the vulva, two hours could pass 
before the heifer was examined for dystocia. At this time, whatever 
assistance was required to deliver a live calf was used. Dystocia 
scores were: (1) normal parturition, (2) token assistance of one person 
by hand (no mechanical assistance) , (3) mechanical assistance required, 
but not dangerous to heifer or calf, (4) caesarian or equivalent assis-
tance required, and (5) malpresentation, position or posture. 
Calf viability was scored as alive or dead at birth, also, time 
from birth to nursing was recorded. If a calf did not nurse within two 
hours of birth, it was fed colostrum via stomach tube and recorded. 
Climatic conditions were recorded at birth. Calf weight was recorded 
within 12 hours after birth and every two weeks until eight weeks of 
age. 
Time of delivery of the placenta was recorded. Placentas were con-
sidered to be retained if not delivered within eight hours of parturition. 
Evaluation of Postpartum Ovarian Luteal Functions 
Weekly uterine palpations were conducted through 40 days post-
partum to evaluate uterine involution. The parameters recorded were 
cervical diameter and horn diameters in millimeters. 
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CHAPTER IV 
DESCRIPTION OF THE DATA ANALYSIS 
Analysis of the data was done based on the following null hypo-
thesis: (1) no effect of the drug on dystocia rate, (2) no effect of 
the drug on pelvic area, (3) no effect of the drug on length of Stage I 
of parturition, (4) no effect of the drug on length of Stage II of 
parturition, (5) no effect of the drug on Stage III of parturition and 
(6) no effect of the drug on calf viability. 
Clinical observations were used to test the drug effect on Stage 
III, dystocia rate, and calf viability. Statistical analysis of the 
clinical data was used to test the remaining null hypotheses. The null 
hypothesis assumes that the treatment and the controls are equal (no 
effect due to treatment) . A statistical analysis was done in order to 
test the null hypothesis. The experiment done was one with two unequal-
sized groups, randomized selection, and independent samples. Where the 
variances in each group were judged to be equal, a standard t test was 
done on the observed mean difference between the treatment and the con-
trol groups in order to test the null hypothesis. A pooled estimate 




(nA - 1) + (nB - 1) 
where n equals the number of observations. 
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The student t test on the observed mean difference was then com-
puted using the following formula: 
t calc 
= JYA - YBJ 
S-
y A - YB 
Where the variances were judged to be unequal, then a t'test 
where t' calc = (xl - x2)/ lsl2;nl + s2 2;n2 was used instead of a stan-
dard t test. 
The observed significance level of 2.5 percent in the data indi-
cates that if all the treatments were equal (the treatment results would 
equal control results) and the samples were taken at random, we could 
expect to see results similar to the one we have less than 2.5 percent 
of the time due to sampling of the population. Therefore, we have 
evidence to reject the null hypothesis. 
TABLE III 
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Zy = 1190.00 
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n = 10 
ye = 119. 00 
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s 2 5248.8889 
ye 
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19596.35 + 924.89 
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t'eale 
TABLE III (Continued) 
= /11121.24 = 105.45 
!Yt - Ye! = 467.69 - 119.oo 
s- 105.45 
Yt ye 





















l:yt = 4960.00 
n = 13 
y = 381.54 
t 
s = 274.33 
yt 
s 2 = 75255.77 
yt 
F eale = 75255. 77 
7515.56 












l:y = 1360.00 
e 
n = 10 




2 s = 7515.56 
ye 
= 10.01 
F tab = 3.87 





TABLE IV (Continued) 
s- 16540.47 80.87 
yt Ye 
t'calc !Yt - Ye! 
381. 59 - 130.00 251. 54 
3.11 = = = = s- 80.87 80.87 
yt Ye 
p < 0.025 
2 sp = 
TABLE V 















'i..y = 700.00 
t 
n = 13 
y = 53.85 
t 
s = 35.95 
yt 
'i.. 2 = 15507.67 
y t 
2 
s = 1292.31 
yt 
'i.. y2 + I. y2 
t c 
(nt - 1) + (n c 
F calc 
F 
= - 1) 
2144. 72 
1292.31 
tab = 3. 87 












I.y = 865.00 
c 
n = 10 
Y = 86.50 c 
46.31 
'i.. 2 = 19302.50 
y c 
s 2 2144.72 
ye 
1.66 








TABLE V (Continued) 
2 2 
1657.63 = ~ + sp = 




iyt - YeJ 
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127.51 + 165.77 
h93.28 = 17 .13 


























Iyt = 1395.00 
n = 13 
yt = 107.31 
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n = 10 
ye = 119.50 











TABLE VI (Continued) 
2 2 5116.82 5116.82 = 32_ + 32_ = + ----
n n 13 10 
t c 
3.93.60 + 511.68 905.28 
/905. 28 30.09 
calc t I Y t - Y c I = .::.1::::...0 7:....:·:..:3=-=1:.....--.....:1==1=-=9..;.·~5..;;..o = 
s- 30.09 
0.41 
y t Ye 
TABLE VII 















I:yt = 3767.00 
n = 13 
yt = 289.77 
s = 18.22 
yt 
I: 2 3982.31 
y t 













I:y = 2901.00 
c 
n = 10 
y = 290.10 
c 
s = 10.22 
ye 
I: 2 = 940.90 
y c 
2 
s = 104.54 
ye 





DF 12 & 9 
F tab = 3. 87 





TABLE VII (Continued) 
2 2 
= sp + ~ = 234.44 + 234.44 
nt nc 13 10 
18.04 + 23.44 41.47 
s- = 141.47 6.44 
yt Ye 
-





















l:yt = 3428.00 




yt = 264.46 






l: 2 + l:y2 y t c 
F calc = 
639.10 = 644.68 
DF 12 & 9 












l:y = 2687.00 
c 
n = 10 
y = 268.70 
c 
s = 25.39 
Ye 






7669.23 + 5802.10 13471. 33 
::: ::: 
(nt - 1) + (n - 1) 21 21 c 
42 
641.49 
TABLE VIII (Continued} 
2 2 641.49 641.49 = ~ + ~ = + = 49.35 + 64.15 = 113.50 n n 13 10 
t c 
- -
lyt - ycl 
calc t = · 
= /113.50 = 10.65 
















LENGTH OF STAGE II IN CONTROL HEIFERS VS 
LENGTH OF STAGE II IN TREATMENT HEIFERS 
WITH CERVICAL DIAMETER > 10 cm. 
AT TREATMENT, (MINS) 


















n = 16 





F calc = 23880.73 
5816.25 
























n = 20 











F tab= 2.76 
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TABLE IX (Continued) 
23880.73 + 5816.25 = 
16 20 1492.55 + 290.81 
= 1783.36 
= 11783.36 = 42.23 
-
t'calc = lyt - ycl = =1~99~-~0~6~-~1~2~7~·~5_0 = 71.56 1.69 




LENGTH OF STAGE II FOR HEIFERS CALVING 
LESS THAN 2 HOURS AND THOSE CALVING 
GREATER THAN OR EQUAL 
TO 2 HOURS (MINS) 

































n = 31 n = 15 
y = 55.48 y = 162. 33 
Sy = 29.56 Sy = 46.56 
t c 
2-s y - ye t 
TABLE x (Continued) 
2 
L:y t = 26217.74 L:/e = 30343.33 
s 2 845.73 y t s 2 2022.89 y e 
Sp 
2 26217.74 + 30343.33 
1285.48 = = 30 + 14 
s 2 s 2 1285.48 1285.48 =~+_£_= + = 41.47 + 85. 70 n n 31 15 
t e 
Syt - ye /127.17 = 11.28 
JYt - Yel 
Cale t = ..... ------
8Yt- Ye 
j55.48 - 162.33j = 
11.28 
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y = 112.61 


























n = 23 
y = 68.04 
Sy = 43.08 
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TABLE XI (Continued) 
zy2 108293.48 zy2 = 40836.96 
Sy2 = 4922.43 Sy2 1856.23 
z 2 2 
Sp2 
YA + Zy B 108293.48 + 40836. 96 
= = 2(n - 1) 44 
sy - y = ~2 (sp2 > = /308.12 
A B 22 
17.55 
IYA - YBI 
Cale t = · · = 
8YA- YB 




tab t = 44 DF 





RESULTS AND DISCUSSION 
Limitations and Error 
Observations for pending signs of parturition and signs indicating 
that Stage I had begun were made by senior veterinary students and the 
principal investigators. This placed an error on the experiment depen-
dent on the observers' ability to detect the subtle or non-existent 
signs of Stage I. There was a wide range in ability among the students 
to detect early Stage I. Some students seemed to never miss while 
others could only find cows in Stage I by luck. Therefore, several cows 
which should have been detected were missed completely, and others which 
were detected late in Stage I should have been detected earlier. This 
is one reason for the wide range in the variances for Stage I data. 
The most consistent method we could use to find cows in Stage I 
with the cervix less than fully dilated was to check the sacrosciatic 
ligament on all cows twice daily, spend all spare time watching the cows 
for subtle changes in their attitude or habits, and doing vaginal exami-
nation on cows with loose sacrosciatic ligaments every four to six hours. 
On more than one occasion, cows calved without showing any impending 
signs of parturition (i.e., udder filling, cervical plug, loose sacro-
sciatic) for a detectable length of time. 
The major factor which caused the wide range in the variances for 
Stage I data was the extent of cervical dilation at treatment. For 
50 
those cows with cervical dilation of greater than ten centimeters, 
the effect of treatment was negligible. An analysis by a t' test 
showed no significant mean difference at the 5% level between the 
treatment animals with greater-than-ten-centimeter cervical dilation 
at treatment versus the control animals. 
TABLE XII 
LENGTH OF STAGE II IN CONTROL HEIFERS VS 
LENGTH OF STAGE II IN TREATMENT HEIFERS 
WITH CERVICAL DIAMETER > lOcm 
AT TREATMENT. (MINS) 
Treatment > 10 cm. 
Ey = 3185.00 
t 
n = 16 
199.06 
DF 19 & 15 
Control 
Ey = 2550.00 
c 
n = 20 
127.50 
The relationship between cervical diameter at treatment and 
length of delay can be seen in the graphs l and 2 (see appendix) . 
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Another problem which contributed error and the variance difference 
was a very poor A.I. conception. Therefore, we were not able to place 
any faith on the breeding dates and predicting parturition. 
52 
Also, the expected dystocias from the Hereford bull did not occur. 
Of the 46 cows used, 35 calved with no assistance. Of the 11 requir-
ing assistance, two were due to malposture or position, and the re-
maining nine were all soft tissue restructions, i.e., vulva, hymen. 
No animal required assistance because of pelvic restriction. There-
fore, evaluation of this drug to alleviate or lessen dystocias in 
heifers could not be done. 
Shortly after the trial began, we were notified that the expira-
tion date on the placebo had expired and could be precipitating. It 
was forming a precipitate and was removed from use, and a saline 
placebo was used. This eliminated the blind assessment and may have 
contributed to some bias. 
Pelvic Area 
Pelvic area of the dam has been shown to have a high correlation 
with dystocia with heavy birth weights increasing the correlation (70). 
The trial was designed to use this multiple correlation in testing the 
effect of the drug but, as previously stated, the expected dystocias 
due to high birth weight did not occur. This left only the effect of 
the drug on pelvic area to be evaluated. The idea was postulated that 
increased time in Stage I could allow the soft tissue attachments of 
the pelvis to continue to relax, thus increasing their stretch during 
Stage II and allowing a larger pelvic area. 
By measuring the pelvic area with the pelvimeter at treatment and 
then immediately postpartum, a significant increase in the stretching of 
the soft tissue attachments yielding an increased pelvic area should be 
detected. Measurements during this trial showed no statistically sig-
nificant difference between treatment and control pelvic areas for 
either group. 
Schebitz (71) showed that the pelvic lumen was greatest during 
abdominal contractions in lateral recumbancy and indicated that pelvic 
lumen increases may be a dynamic one, i.e., during an abdominal con-
traction. 
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This would point to the possibility of the drug effect being a 
dynamic one and not detectable if measured just before and after partu-
rition. If there was an increased dynamic effect of the drug due to an 
increased relaxation of the soft tissue pelvic attachments, then ab-
dominal contractions should have caused an increase in the pelvic lumen. 
If this effect were present, then Stage II for the treatment group 
should have been easier, therefore shorter. Since no significant dif-
ference was found in Stage II length, then this increase in dynamic 
effect for the treatment group probably does not exist. 
TABLE XIII 
PELVIC AREA AT BIRTH--GROUP A (cm2) 
Treatment Control 
l:yt 3767.00 l:y 2901. 00 c 
n = 13 n = 10 
yt = 289. 77 
ye = 290.10 
TABLE XIV 
PELVIC AREA AT BIRTH--GROUP B (cm2) 
Treatment 
l:yt "' 3408.00 
n = 13 
yt = 264.46 
Stage I Delay 
Control 
l:y = 2687.00 
c 
n = 10 
y = 268.70 
c 
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The length of Stage I was greatly increased due to the treatment. 
The mean difference for both groups A and B was significant at the 
0. 025 level. 
TABLE XV 
STAGE I--GROUP A (MINS) 
Treatment 
6080.00 
n = 13 
yt"' 467.69 
Range = 75-1350 











STAGE I--GROUP B (MINS) 
Treatment Controls 
Eyt 4960.00 Ey 1360.00 c 
n = 13 n = 10 
yt = 381.54 ye = 130.00 
Range = 30-900 Range = 30-330 
p < 0.025 DF 21 
There is evidence against the null hypothesis of no effect of 
the drug on the length of Stage I. 
The variance within each group used in the analysis was very 
large making a detailed analysis of this very cumbersome and diffi-
cult. This variance was caused primarily by the ability of the ob-
server to detect cows early in Stage I and individual cow variation. 
As graphs 1 and 2 illustrated, length of delay is shortened as cervi-
cal diameter at treatment increased. 
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As already shown the drug had no delay on parturition after the 
cervix reached 10 cm or greater in dilation. At this stage of dilation 
fetal membranes and appendages are protruding through the cervix stimu-
lating abdominal contractions. This demonstrates the ineffectiveness 
of tocolysis in competition with stimuli for abdominal contractions. 
STAGE II 
The length and, therefore, the ease of Stage II was not affected 
by treatment. The mean difference for either group, A or B was not 
significant at the 0.025 level. 
TABLE XVII 
STAGE II--GROUP A (MINS} 
Treatment 
L:yt = 700.00 
n = 13 
yt = 53.85 
Range = 15-145 
Control 
L:y = 865.00 
c 
n = 10 
ye = 86.50 
Range = 20-150 
TABLE XVIII 
STAGE II--GROUP B (MINS} 
Treatment 
L:yt = 1395.00 
n = 13 
yt = 107.31 
Range = 5-240 
Control 
L:y = 1195. 00 
c 
n = 10 
y = 119.50 
c 
Range = 45-270 
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Since there was no detectable affect of the drug on Stage II 
the animals were grouped according to pelvic areas irrespective of 
treatment and controls. This was done to evaluate the length of 
Stage II for those animals with large pelvic areas vs. those with 
small pelvic areas. The mean difference between groups (A- -
y 
68.04; B- - = 112.61) was significant at the .025 level. 
y 
TABLE XIX 
LENGTH OF STAGE II BETWEEN GROUPS (MINS} 
A 
'f.yA = 1565.00 




n = 23 
112.61 
In this study of the 15 animals requiring some assistance with 
birth 6 were in group A and 10 were in group B. The significant mean 
difference between groups indicated that pelvic area had more effect 
on the length and ease of Stage II then did the treatment. 
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Stage II: Less Than Two Hours, Greater 
Than or Equal to Two Hours 
Since there was no affect on Stage II due to treatment, we wanted 
to look at the length of Stage II for those cows calving within the 2 
hour limit. The mean difference for those < 2 hours was - = 55.48 
y 
minutes and those > 2 hours was - = 162.33. 
y 
TABLE XX 
LENGTH OF STAGE II FOR HEIFERS CALVING 
LESS THAN 2 HOURS AND THOSE CALVING 
GREATER THAN OR EQUAL 
TO 2 HOURS (MINS) 
< 2 Hours > 2 Hours 
'i.y = 1720.00 'i.y = 2435.00 
n = 31 n = 15 
= 55.48 y = 162.33 
y 
p < .001 
DF = 30 & 14 
Due to the protocol of this trial those cows going over 2 hours 
and not about to finish Stage II were assisted. This would shorten 
the true length of Stage II for those going over 2 hours. In the 
group ~ hours (n = 15) only 4 were unassisted. The mean difference 
was significant at the .001 level. The mean value of 55.48 minutes 
for the less than 2 hour group was shorter than expected. This indi-
58 
cates that calving assistance may be warranted sooner than presently 
thought. Additional data needs to be evaluated to substantiate this 
observation. 
Stage III 
By definition, Stage III includes both the shedding of the fetal 
membrane and uterine involution. Only one cow failed to shed her mem-
brane. Delay of Stage I had no effect on the shedding of the fetal 
membrane. 
Uterine involution was evaluated by weekly rectal palpation 
through 40 days postpartum. There was no palpable difference in the 
uterine involution for the treatment and control groups. 
Calf Viability 
There was no effect on calf viability due to treatment. One calf 
was born dead in group A treatment, but no other calves showed any 
effects from Stage I delay. One cow was delayed for 22 hours, and her 
calf was up and nursing well within the two-hour limit. 
When you look at groups irrespective of treatment; group A, 2 
calves did not nurse within the 2 hour limit and in group B, 7 calves 
did not nurse within the 2 hour limit and required assistance. With 
the large main difference for the length of Stage II between groups, 
the smaller pelvic area appeared to affect calf viability. 
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